Status: Recruiting
Study of TGM-312-SC01 in Healthy Participants and Adults With MASH
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) effects of single ascending doses of TGM-312-SC01 in healthy adults and multiple ascending doses in patients with metabolic dysfunction-associated steatohepatitis (MASH).
Participants needed: 99
Trial details
Phase: Phase 1, Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Tangram Therapeutics PlcUpdated: May 19, 2026Locations: 1
Eligibility criteria
Adults aged 18 to 70 years who are able to provide written informed consent. [+2]
Clinically significant medical conditions, laboratory abnormalities, or other fi... [+3]